Ware Olivia C 4

What Happened

• Olivia C. Ware, a director of Contineum Therapeutics, was granted a derivative award (stock option) for 19,000 shares on 2026-06-26. The Form 4 reports an acquisition (code A) at $0.00 per share (no cash paid at grant). This is a compensation grant, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-26; transaction type: Award/Grant (derivative) for 19,000 shares; reported price: $0.00.
• Vesting: Option vests in full on the earlier of (i) June 26, 2027 (one-year anniversary) or (ii) the next regular annual meeting, subject to continued service (per footnote referencing the 2024 Equity Incentive Plan and the Non‑Employee Director Compensation Program).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Filing timeliness: Reported on 2026-06-26 for a transaction on the same date (appears timely).
• Transaction code: A (award/grant); reported as a derivative transaction.

Context

• This is a routine director compensation grant under the company’s equity plan, intended to compensate non-employee board members. It does not represent an immediate purchase of shares and may not indicate the director’s view on the company’s near-term stock performance.